Oligodendrocyte progenitor cells promote neovascularization in glioma by disrupting the blood-brain barrier

Cancer Research

Volumn 74, Issue 4, 2014, Pages 1011-1121

  Huang, Yujie ^a   Hoffman, Caitlin ^a   Rajappa, Prajwal ^a   Kim, Joon Hyung ^a   Hu, Wenhuo ^b   Huse, Jason ^b   Tang, Zhongshu ^c   Li, Xuri ^c   Weksler, Babette ^a   Bromberg, Jacqueline ^b   Lyden, David C ^a   Greenfield, Jeffrey P ^a,d  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c NATIONAL EYE INSTITUTE   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; CAPILLARY PERMEABILITY; DISEASE PROGRESSION; GLIOMA; LYMPHOKINES; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; OLIGODENDROGLIA; PLATELET-DERIVED GROWTH FACTOR; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; STEM CELLS; TUMOR CELLS, CULTURED; TUMOR MICROENVIRONMENT;

EID: 84894236233     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-1072     Document Type: Article

References (48)

1. Charles NA, Holland EC, Gilbertson R, Glass R, Kettenmann H. The brain tumor microenvironment. Glia 2011;59:1169-80.
2. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer 2009;9:239-52.
3. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
4. Abbott NJ, Ronnback L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 2006;7:41-53.
5. Barres BA, Raff MC. Axonal control of oligodendrocyte development. J Cell Biol 1999;147:1123-8.
6. Shih AH, Dai CK, Hu XY, Rosenblum MK, Koutcher JA, Holland EC. Dose-dependent effects of platelet-derived growth factor-B on glial tumorigenesis. Cancer Res 2004;64:4783-9.
7. Huse JT, Holland EC. Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer 2010;10:319-31.
8. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010;17:98-110.
9. Liu C, Sage JC, Miller MR, Verhaak RGW, Hippenmeyer S, Vogel H, et al. Mosaic analysis with double markers reveals tumor celloforigin in glioma. Cell 2011;146:209-21.
10. Sugiarto S, Persson AI, Munoz EG, Waldhuber M, Lamagna C, Andor N, et al. Asymmetry-defective oligodendrocyte progenitors are glioma precursors. Cancer Cell 2011;20:328-40.
11. Lindberg N, Kastemar M, Olofsson T, Smits A, Uhrbom L. Oligoden-drocyte progenitor cells can act as cell of origin for experimental glioma. Oncogene 2009;28:2266-75.
12. Persson AI, Petritsch C, Swartling FJ, Itsara M, Sim FJ, Auvergne R, et al. Non-stem cell origin for oligodendroglioma. Cancer Cell 2010; 18:669-82.
13. Dawson MR, Polito A, Levine JM, Reynolds R. NG2-expressing glial progenitor cells: an abundant and widespread population of cycling cells in the adult rat CNS. Mol Cell Neurosci 2003;24: 476-88.
14. Geha S, Pallud J, Junier MP, Devaux B, Leonard N, Chassoux F, et al. NG2/Olig2 cells are the major cycle-related cell population of the adult human normal brain. Brain Pathol 2009;20:399-411.
15. Phillips HS, Kharbanda S, Chen RH, Forrest WF, Soriano RH, Wu TD, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006;9:157-73.
16. Tang Z, Arjunan P, Lee C, Li Y, Kumar A, Hou X, et al. Survival effect of PDGF-CC rescues neurons from apoptosis in both brain and retina by regulating GSK3beta phosphorylation. J Exp Med 2010; 207:867-80.
17. Newcomb EW, Tamasdan C, Entzminger Y, Arena E, Schnee T, Kim M, et al. Flavopiridol inhibits the growth of GL261 gliomas in vivo: implications for malignant glioma therapy. Cell Cycle 2004;3:230-4.
18. Reilly KM, Loisel DA, Bronson RT, McLaughlin ME, Jacks T. Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects. Nat Genet 2000;26:109-13.
19. Miyatake SI, Martuza RL, Rabkin SD. Defective herpes simplex virus vectors expressing thymidine kinase for the treatment of malignant glioma. Cancer Gene Ther 1997;4:222-8.
20. Weksler BB, Subileau EA, Perriere N, Charneau P, Holloway K, Leve-que M, et al. Blood-brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J 2005;19:1872-4.
21. Kawakami K, Kioi M, Liu Q, Kawakami M, Puri RK. Evidencethat IL-13R alpha-2 chain in human glioma cells is responsible for the antitumor activity mediated by receptor-directed cytotoxin therapy. J Immun-other 2005;28:193-202.
22. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005;438:820-7.
23. Huang YJ, Song N, Ding YP, Yuan SP, Li XH, Cai HC, et al. Pulmonary vascular destabilization in the premetastatic phase facilitates lung metastasis. Cancer Res 2009;69:7529-37.
24. Peinado H, Rafii S, Lyden D. Inflammation joins the "Niche". Cancer Cell 2008;14:347-9.
25. Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B, et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007;11:69-82.
26. Seo JH, Miyamoto N, Hayakawa K, Pham LD, Maki T, Ayata C, et al. Oligodendrocyte precursors induce early blood-brain barrier opening after white matter injury. J Clin Invest 2013;123:782-6.
27. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97-109.
28. Fredriksson L, Nilsson I, Su EJ, Andrae J, Ding H, Betsholtz C, et al. Platelet-derived growth factor C deficiency in C57BL/6 mice leads to abnormal cerebral vascularization, loss of neuroependymal integrity, and ventricular abnormalities. Am J Pathol 2012;180:1136-44.
29. Sim FJ, McClain CR, Schanz SJ, Protack TL, Windrem MS, Goldman SA. CD140a identifies a population of highly myelinogenic, migration-competent and efficiently engrafting human oligodendrocyte progenitor cells. Nat Biotechnol 2011;29:934-U123.
30. Camelo-Piragua S, Jansen M, Ganguly A, Kim JC, Louis DN, Nutt CL. Mutant IDH1-specific immunohistochemistry distinguishes diffuse astrocytoma from astrocytosis. Acta Neuropathol 2010;119: 509-11.
31. Capper D, Sahm F, Hartmann C, Meyermann R, von Deimling A, Schittenhelm J. Application of mutant IDH1 antibody to differentiate diffuse glioma from nonneoplastic central nervous system lesions and therapy-induced changes. Am J Surg Pathol 2010;34:1199-204.
32. Morello N, Bianchi FT, Marmiroli P, Tonoli E, Menendez VR, Silengo L, et al. A role for hemopexin in oligodendrocyte differentiation and myelin formation. PLoS ONE 2011;6:e20173.
33. Ziv Y, Avidan H, Pluchino S, Martino G, Schwartz M. Synergy between immune cells and adult neural stem/progenitor cells promotes functional recovery from spinal cord injury. Proc Natl Acad Sci USA 2006;103:13174-9.
34. Lecca D, Trincavelli ML, Gelosa P, Sironi L, Ciana P, Fumagalli M, et al. The recently identified P2Y-like receptor GPR17 is a sensor of brain damage and a new target for brain repair. PLoS ONE 2008;3:e3579.
35. Chang A, Nishiyama A, Peterson J, Prineas J, Trapp BD. NG2-positive oligodendrocyte progenitor cells in adult human brain and multiple sclerosis lesions. J Neurosci 2000;20:6404-12.
36. Zawadzka M, Rivers LE, Fancy SPJ, Zhao C, Tripathi R, Jamen F, et al. CNS-resident glial progenitor/stem cells produce Schwann cells as well as oligodendrocytes during repair of CNS demyelination. Cell Stem Cell 2010;6:578-90.
37. Fomchenko EI, Dougherty JD, Helmy KY, Katz AM, Pietras A, Brennan C, et al. Recruited cells can become transformed and overtake PDGF-induced murine gliomas in vivo during tumor progression. PLoS ONE 2011;6:e20605.
38. Giese A, Bjerkvig R, Berens ME, Westphal M. Cost of migration: Invasion of malignant gliomas and implications for treatment. J Clin Oncol 2003;21:1624-36.
39. Grinspan JB, Stern JL, Pustilnik SM, Pleasure D. Cerebral white matter contains Pdgf-responsive precursors to O2a cells. J Neurosci 1990; 10:1866-73.
40. Orentas DM, Miller RH. Regulation of oligodendrocyte development. Mol Neurobiol 1998;18:247-59.
41. Blouw B, Song HQ, Tihan T, Bosze J, Ferrara N, Gerber HP, et al. The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell 2003;4:133-46.
42. Charles N, Ozawa T, Squatrito M, Bleau AM, Brennan CW, Hambard-zumyan D, et al. Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells. Cell Stem Cell 2010;6:141-52.
43. Su EJ, Fredriksson L, Geyer M, Folestad E, Cale J, Andrae J, et al. Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke. Nat Med 2008;14:731-7.
44. Crawford Y, Kasman I, Yu LL, Zhong CL, Wu XM, Modrusan Z, et al. PDGF-C mediates the angiogenic and tumorigenic properties of fibro-blasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 2009;15:21-34.
45. di Tomaso E, Snuderl M, Kamoun WS, Duda DG, Auluck PK, Fazlollahi L, et al. Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape. Cancer Res 2011;71:19-28.
46. Ricci-Vitiani L, Pallini R, Biffoni M, Todaro M, Invernici G, Cenci T, et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 2010;468:824-8; corrigendum 2011;477:238.
47. Wang R, Chadalavada K, Wilshire J, Kowalik U, Hovinga KE, Geber A, et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature 2010;468:829-U128.
48. Cheng L, Huang Z, Zhou WC, Wu QL, Donnola S, Liu JK, et al. Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell 2013;153:139-52.